Ligand validation:7HQU

EVE: 1H-benzimidazole-2-sulfonamide

EVE is a Ligand Of Interest in 7HQU designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
7HQU_EVE_B_401	96%	37%	0.065	0.974	1.36	1.1	1	1	2	0	100%	0.79
7HQU_EVE_A_402	96%	35%	0.068	0.975	1.35	1.21	1	2	0	0	100%	0.79
7HQU_EVE_A_401	90%	41%	0.076	0.958	1.17	1.13	1	1	8	0	100%	0.79
7HQU_EVE_B_402	87%	42%	0.079	0.95	1.11	1.14	1	1	7	0	100%	0.79
7HR5_EVE_B_402	100%	30%	0.045	0.985	1.63	1.17	1	2	3	0	100%	0.81
3S72_EVE_B_1	98%	3%	0.06	0.985	3.5	2.6	1	6	0	0	100%	1
5RTC_EVE_A_201	58%	5%	0.112	0.889	3.08	2.21	8	5	0	0	100%	0.7

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.